NEW YORK, Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The...
Related Questions
How might these claims affect NeoGenomics' financial performance and revenue projections?
Could the investigation trigger a material adverse change (MAC) clause in any of NeoGenomics' existing agreements?
What is the potential legal exposure or liability for NeoGenomics if the claims proceed?
What is the expected timeline for the investigation and any potential litigation or settlement?
Will the outcome of the investigation likely influence institutional or retail investor sentiment toward NEO?
How have similar securities class‑action suits impacted peer companies in the genomics sector?
What specific allegations are Pomerantz LLP investigating regarding NeoGenomics?